Pi-Cardia Receives $10M Investment from Major Medical Company

January 11, 2016 | Pi-Cardia, a portfolio company in Israeli fund Clal Biotechnologies Industries, has sold a 25% equity share to an unnamed major medical instrument company in exchange for $10 million. Pi-Cardia is developing a novel low profile catheter for the treatment of aortic stenosis (the narrowing of the heart valve). The company’s technology, which in undergoing clinical trials, creates fractures in valve calcifications, without injuring the surrounding soft tissue. This treatment, which only takes several seconds, is intended to increase the effectiveness and lifespan of the valve.